

Minimally Invasive Treatment of Periodontal Infrabony Defects – Pilot Randomized Clinical Trial

Rolo T*, Baptista I, Messias A, Caramelo F, Matos S Dentistry Department - Faculty of Medicine - University of Coimbra - Portugal

Introduction


Clinical Protocol

The maintenance of graft stability and grafted anatomy during healing, due to the pressure exerted by soft tissues and the possible migration of particles, remains an issue when using particulate bone substitutes (Matos et al. 2012). Biphasic calcium sulphate is a bioresorbable, osteoconductive, fast setting synthetic bone grafting material, with physical properties not affected by the presence of blood or saliva, which can act as a binder when combined with other granulated bone graft substitutes (Horowitz et al. 2012). Minimally invasive surgical technique (MIST) has been proposed for the regeneration of periodontal infrabony defects (Cortellini & Tonetti 2007a), in order to minimize the surgical trauma and the tendency for collapse of interproximal tissues, enhance flap stability and wound healing, reduce surgical chair time and patient morbidity (Cortellini & Tonetti 2007b, Cortellini et al. 2008).

Aim

To evaluate the efficacy of a combination of a fast setting synthetic bone substitute with binding capacities (biphasic calcium sulphate (BondBone™, MIS Implant Technologies, Israel) - BB) and a xenograft (Bio-Oss™, Geistlich, Switzerland) versus open flap debridment, through a minimally invasive surgical technique (MIST), for the treatment of periodontal infrabony defects.

Material & Methods



- Protocol approved by the Ethical Commitee of the Faculty of Medicine University of Coimbra (Portugal) and in accordance with Helsinski's Declaration for human clinical research.
- Digital standardized intraoral radiographs were obtained using an acrylic customized x-ray positioning stent combined with Dentsply Rinn XCP-DS® system, built for Gendex® Visualix® eHD 37.5 × 25.5 mm sensor (Gendex Dental Systems, IL, EUA) and calibrated with a 2mm metal sphere. X-ray tube stabilization was achieved with polyvinylsiloxane (Messias et al. 2013).
- Outcomes measured by 2 independent blind assessors at 0, 6 and 12 months.
- Primary outcome measure: Changes in clinical attachment level (CAL).
- Secondary outcomes measures: Changes in probing pocket depth (PPD), gingival recession (Re) and in radiographic marginal bone levels (RAD) (distance from CEJ to base of defect (CEJ_BD), distance from alveolar crest to base of defect (AC_BD), defect's angle (angle)). Post-operative complications and adverse events. Patient's evaluation of treatment and aesthetics by anonymous questionnaire.

Results

Table 1 - Patient's baseline of	haracteristics.			Table 2	– Post-op
	Control (10)	Test (10)	р		
Age	52.10 ± 13.44	50.70 ± 13.63	0.820 ¹		Complica
Sex (F/M)	6 (60%) / 4 (40%)	6 (60%) / 4 (40%)	1.000 ²		
Smokers (<10 cig/day)	2 (20%)	1 (10%)	1.000 ²		Uneven
ASA Classification				Control	Dehisce
ASA I	5 (50%)	3 (30%)	0.650 ²	Group	(minc
ASA II	5 (50%)	7 (70%)			Suppura
Full mouth plaque score	15.53 ± 3.64	14.49 ± 4.35	0.436 ¹		
Full mouth marginal	0.30 ± 0.74	1.08 ± 1.25	0.739 ¹		L la aveca
bleeding score				T	Uneven
Full mouth bleeding on	7.38 ± 2.48	6.37 ± 3.11	0.393 ¹	Test	Dehisce
probing score				Group	Uneven Dehisce (minc
Intrabony defect depth	6.700 ± 2.003	6.700 ± 1.829	0.969 ¹		Suppura
Predominantly 2, 3 walls & c	ombined defects ir	both groups.	0.221 ²		
¹ t-Student Test; ² Fisher's Ex	act Test				

Table 3 - Patient self-reported post-operative pain & med	dication
---	----------

	Control (10)	Test (10)	р ¹	
Post-operative pain	2.30 ± 2.50	1.60 ± 1.65	0.469	
VAS 0-10 scale				
Nº anti-inflamatory pills intake	2.90 ± 2.23	2.50 ± 2.32	0.763	
¹ t-Student Test				

¹ t-Stud	lent	Test	

Tables 4, 5, 6 - Post-operative changes in clinical periodontal parameters (PPD, Re, CAL)

	PPD_0M	PPD_6M	PPD_12M	ΔPPD_0 - 12M	
	Mean ± SD (mm)	Mean ± SD (mm)	Mean ± SD (mm)	Mean ± SD (mm)	
	(mmn)	(mmn)	(mmn)	(mm)	
Control	6,8 ± 0,919	4,2 ± 1,135	3,7 ± 1,337	3,1 ± 1,37	

Table 2 – Post-operative complications & adverse events							
	Complications	1st week	2nd week	3rd week	4th week	6th week	
Combined	Uneventfull	9 (90%)	9 (90%)	10 (100%)	10 (100%)	10 (100%)	
Control Group	Dehiscence (minor)	1 (10%)	1 (10%)	0 (0%)	0 (0%)	0 (0%)	
	Suppuration	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
Test	Uneventfull	7 (70%)	5 (50%)	7 (70%)	10 (100%)	10 (100%)	
Test Group	Dehiscence (minor)	3 (30%)	5 (50%)	3 (30%)	0 (0%)	0 (0%)	
	Suppuration	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	

Table 7 - Post-operative changes in radiographic parameters

	Control Group								
Variable	ΔB	∆Baseline – 6 Months		∆Baseline – 12 Months					
	\overline{x}	S	IC 95%	\overline{x}	S	IC 95%			
CEJ_BD	1.09	1.52	[0.01;2.18]	1.35	1.65	[0,17;2.52]			
AC_BD	1.38	1.72	[0.15;2.61]	1.69	1.74	[0.44;2.93]			
Angle	-12.60	16.69	[-24.54;-0.66]	-14.90	16.31	[-26.57;-3.23]			
	Bone fill at 12 months: 32,13%								

Test Group							
Variable	ΔE	aseline ·	- 6 Months	ΔBa	aseline -	- 12 Months	
	x	S	IC 95%	\overline{x}	S	IC 95%	
CEJ_BD	2.30	1.34	[1.34;3.26]	2.62	1.42	[1.60;3.63]	



Initial situation





Test Group





Initial probing depth – 7mm



MIST surgical access



Infrabony depth – 8mm

Infrabony width – 3mm



OFD





12 months probing depth – 4mm



Initial probing depth - 6mm



Infrabony depth – 8mm



Infrabony width – 4mm



Regeneration (BB + xenograft)



Modified mattress suture




12 months probing depth – 3mm

Pre-operative standardized rx

7,1 ± 1,287	3,7 ± 0,483	3,1 ± 0,994	4,0 ± 1,25	0.142
Re_0M Mean ± SD (mm)	Re_6M Mean ± SD (mm)		ΔRe_0 - 12M Mean ± SD (mm)	p 1
1,7 ± 2,003	2,4 ± 2,221	2,4 ± 2,221	-0,70 ± 0,67	1
1,0 ± 0,943	1,7 ± 1,703	1,7 ± 1,703	-0,70 ± 0,95	1
CAL_0M Mean ± SD (mm)	CAL_6M Mean ± SD (mm)	CAL_12M Mean ± SD (mm)	ΔCAL_0 - 12M Mean ± SD (mm)	p 1
8,5 ± 2,273	6,6 ± 1,776	6,1 ± 2,132	2,4 ± 1,17	0.089
		4,8 ± 2,150	3,3 ± 1,06	0.009
	Re_0M Mean ± SD (mm) 1,7 ± 2,003 1,0 ± 0,943 CAL_0M Mean ± SD (mm)	Re_OM Re_6M Mean ± SD Mean ± SD (mm) (mm) 1,7 ± 2,003 2,4 ± 2,221 1,0 ± 0,943 1,7 ± 1,703 CAL_0M CAL_6M Mean ± SD (men ± SD (mm) (mm)	Re_OM Re_6M Re_12M Mean ± SD Mean ± SD Mean ± SD (mm) (mm) (mm) 1,7 ± 2,003 2,4 ± 2,221 2,4 ± 2,221 1,0 ± 0,943 1,7 ± 1,703 1,7 ± 1,703 CAL_0M CAL_6M CAL_12M Mean ± SD Mean ± SD Mean ± SD (mm) (mm) (mm)	Re_0M Re_6M Re_12M ARe_0 - 12M Mean ± SD Mean ± SD Mean ± SD Mean ± SD (mm) (mm) (mm) (mm) 1,7 ± 2,003 2,4 ± 2,221 2,4 ± 2,221 -0,70 ± 0,67 1,0 ± 0,943 1,7 ± 1,703 1,7 ± 1,703 -0,70 ± 0,95 CAL_0M CAL_6M CAL_12M ACAL_0 - 12M Mean ± SD Mean ± SD Mean ± SD Mean ± SD (mm) (mm) (mm) (mm) (mm)

AC_BD 2.65 1.22 [1.78;3.53] **2.95** 1.18 [2.10;3.80] Angle -20.08 6.88 [-25.01;-15.16] -23.31 7.04 [-28.35;-18.27] Bone fill at 12 months: 60.58%


t-Student Test



Acrylic customized and calibrated x-ray positioning stent



Post-operative healing was achieved uneventfully in the majority of cases. The test group reported a higher frequency of minor dehiscences, mainly with modified papilla preservation flap, which selfresolved in the first 3 post-operative weeks. Factors like the apico-coronal location of the first incision or the macro and micro-porosity of the combined regenerative materials could compromise the revascularization of the papilla or of the defect and/or the stability of the initial blood clot. Regarding main clinical periodontal parameters, both groups showed significant improvements after 12 months. Intergroup comparison evidenced a tendency for better outcomes for the test group vs control group, regarding average PPD reduction (4.0±1.25mm vs 3.1±1.37mm, respectively) and CAL gain (3.3±1.06mm vs 2.4±1.06mm), despite not reaching statistically significant differences. Radiographically, the test group showed a significant superior result in terms of defect bone fill. These results are in accordance with the published literature on minimally invasive surgical technique (Trombelli et al. 2010, Cortellini & Tonetti 2011, Ribeiro et al. 2011, Mishra et al. 2013, Ghezzi et al. 2016).



Pre-operative standardized rx



12 months post-operative rx

12 months post-operative rx

disclosure This study was supported by

MIS Implant Technologies (Israel). All the authors disclaim to have no conflict of interest with the funding entity of this study, nor with any of the manufacturers of the materials used in this clinical trial.



Conclusions

1- Within the limits of this pilot study, both MIST and MIST with the combined regenerative materials resulted in significant improvements in terms of soft and hard tissues outcomes at 12 months.

2- This initial study was not able to detect a significant difference between treatments. Nevertheless, in spite of some minor adverse postoperative reaction, it is suggested that in more challenging defects, as for non-contained morphology, the combination of MIST approach with the tested biomaterials can have a beneficial added effect in terms of improving PPD reduction and CAL gain.

